BioHarvest Sciences (NASDAQ: BHST) outlined its commercial and operational roadmap during the Q3 Investor Summit Group Virtual Conference on August 26, 2026, emphasizing scaling of its plant-cell platform and near-term revenue targets.
The company reported 2025 revenue of approximately $35 million, with over $2 million generated from its contract development and manufacturing organization segment. For 2026, BioHarvest guided consolidated revenue between $37 million and $40 million, driven by direct-to-consumer sales and CDMO manufacturing. Direct-to-consumer revenue is projected at $33 million to $35 million, up from 2025 levels.
Chief Executive Officer Ilan Sobel highlighted the company’s Botanical Synthesis process, which uses a single plant sample to create cell banks and produce dried powder via 3-week bioreactor cycles. This method avoids genetic modification while addressing supply risks tied to natural agriculture, Sobel said. BioHarvest holds 15 patents and has invested roughly $100 million in technology development.
The company’s flagship product, VINIA, a red grape cell supplement, has generated cumulative sales exceeding $100 million since commercialization, with about 20% of revenue coming from Amazon and the remainder via BioHarvest’s website. Each 400 mg capsule contains piceid resveratrol amplified 100 times compared to natural sources, delivering the equivalent of 1,000 grapes or one bottle of red wine without sugar or alcohol.
BioHarvest also detailed progress on its olive-based product, which has completed all development stages and is ready for manufacturing. Its active molecule, verbascoside, is amplified 15 times versus natural sources. Additionally, the company secured a fragrance supply agreement valued between $20 million and $30 million for a 20-ton supply over 2027–2028, with BioHarvest owning 20% of the molecule. A separate saffron product includes ownership of 25% of the saffron molecule, comprising safranal, picrocrocin, and crocin.
Operational capacity currently stands at 20 to 25 tons, supported by a new manufacturing facility funded by a $21 million capital raise completed in late 2024. The company reported a net loss of $0.53 per share over the last twelve months and negative free cash flow of $10.75 million during the same period, despite a gross profit margin of nearly 59%.
